Skip to main content
. 2024 Jan 15;16(2):362. doi: 10.3390/cancers16020362

Figure 3.

Figure 3

Axial and sagittal images of an SBRT treatment plan delivered to a patient enrolled in the SPARTACUS clinical trial. Note the conformality of the 95% prescription isodose line (yellow arrow) outlined in yellow around PTV volumes (in dark blue) and the homogenous dose distribution within treated volumes with absence of pockets of 105% isodose lines (blue arrow).